Scott Ferguson’s Bristol-Myers Squibb BMY Stock Holding History

Scott Ferguson’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-2,070,000	Closed	-$113M	–	13
2017 Q1	$113M	Buy	+2,070,000	New	+$114M	3.65%	11

Other funds holding BMY

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Scott Ferguson's BMY Position: Q2 2017 in Review

Scott Ferguson sold out of Bristol-Myers Squibb (BMY) in Q2 2017, closing a stake of 2,070,000 shares — an estimated $113M sold.

Scott Ferguson first reported a position in BMY in Q1 2017 and held it in 1 quarter. The position peaked at $113M in Q1 2017. 1,595 funds tracked by Wall St. Rank hold BMY as of Q2 2017.

Scott Ferguson reported no remaining Bristol-Myers Squibb position as of Q2 2017 after selling out during the quarter.
Scott Ferguson sold 2,070,000 Bristol-Myers Squibb shares in Q2 2017, an estimated $113M.
Scott Ferguson first reported a position in Bristol-Myers Squibb in Q1 2017 and held it in 1 quarter.
Scott Ferguson's Bristol-Myers Squibb position peaked at $113M in Q1 2017.
1,595 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2017.

Based on Sachem Head Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.